Codexis, Inc. (CDXS)
NASDAQ: CDXS · Real-Time Price · USD
1.830
+0.060 (3.39%)
At close: Dec 5, 2025, 4:00 PM EST
1.829
-0.001 (-0.05%)
After-hours: Dec 5, 2025, 6:18 PM EST

Company Description

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.

The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis, Inc.
Codexis logo
Country United States
Founded 2002
IPO Date Apr 22, 2010
Industry Biotechnology
Sector Healthcare
Employees 188
CEO Alison Moore

Contact Details

Address:
200 Penobscot Drive
Redwood City, California 94063
United States
Phone 650 421 8100
Website codexis.com

Stock Details

Ticker Symbol CDXS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001200375
CUSIP Number 192005106
ISIN Number US1920051067
Employer ID 71-0872999
SIC Code 2860

Key Executives

Name Position
Dr. Alison Moore Ph.D. President, Chief Executive Officer and Director
Georgia L. Erbez Chief Financial Officer and Chief Business Officer
Senator Byron L. Dorgan M.B.A. Consultant
Dr. Stefan Lutz Ph.D. Chief Scientific Officer
Carrie McKim Director of Investor Relations
Britton Jimenez Senior Vice President of Sales and Marketing
Karen Frechou-Armijo Senior Vice President and Head of Human Resources
John Schiffhauer Senior Vice President of Intellectual Property

Latest SEC Filings

Date Type Title
Dec 5, 2025 SCHEDULE 13G/A Filing
Nov 21, 2025 144 Filing
Nov 14, 2025 SCHEDULE 13G/A Filing
Nov 7, 2025 SCHEDULE 13G/A Filing
Nov 6, 2025 10-Q Quarterly Report
Nov 6, 2025 8-K Current Report
Nov 5, 2025 SCHEDULE 13G/A Filing
Oct 14, 2025 144 Filing
Oct 14, 2025 144 Filing
Aug 14, 2025 SCHEDULE 13G/A Filing